Hepatitis Clinical Trial
Official title:
Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma
The propose of this study is to identification of a group of specific amplitude-modulated frequencies of low intensity electromagnetic fields that is associated with biofeedback upon exposure to in patients with hepatitis B carries with or without hepatocellular carcinoma.
Patients will be exposed by different specific amplitude-modulated frequencies of low intensity electromagnetic fields for 30 min. During the exposure, autonomic response with be recorded in order to identify biofeedback response. Differences in group of frequencies is expected in patients with hepatitis B carries with or without hepatocellular carcinoma. ;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05989958 -
The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure
|
Phase 1 | |
| Not yet recruiting |
NCT06395129 -
Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
|
||
| Terminated |
NCT01443923 -
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
|
Phase 4 | |
| Completed |
NCT00679692 -
Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease
|
N/A | |
| Completed |
NCT00300209 -
Manhattan HIV/Hepatology Brain Bank
|
N/A | |
| Recruiting |
NCT05563961 -
A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers
|
N/A | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Completed |
NCT00160407 -
Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 4 | |
| Recruiting |
NCT03692897 -
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
|
||
| Completed |
NCT03509688 -
The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial
|
N/A | |
| Recruiting |
NCT02275195 -
Immune Cell Dysfunction in Severe Alcoholic Hepatitis
|
||
| Completed |
NCT01740089 -
Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C
|
Phase 2/Phase 3 | |
| Completed |
NCT00987337 -
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
|
Phase 2 | |
| Completed |
NCT00929786 -
Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity
|
N/A | |
| Completed |
NCT00564642 -
Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity
|
N/A | |
| Completed |
NCT00080236 -
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
|
Phase 2 | |
| Recruiting |
NCT05719480 -
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Liver Cancer
|
||
| Suspended |
NCT04306939 -
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
|
||
| Completed |
NCT03482388 -
Crowdsourcing to Promote HBV and HCV Testing in China
|
N/A |